Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dragonfly Therapeutics
Mayo Clinic
Neonc Technologies, Inc.
Tizona Therapeutics, Inc
Shanghai Henlius Biotech
Werewolf Therapeutics, Inc.
University of California, Davis
City of Hope Medical Center
ImmunityBio, Inc.
Novartis
Bayer
Inhibrx Biosciences, Inc
Sairopa B.V.
Coherus Oncology, Inc.
University of Pittsburgh
Dragonfly Therapeutics
Nanobiotix
ImmuneSensor Therapeutics Inc.
Vyriad, Inc.
Asher Biotherapeutics, Inc.
Xencor, Inc.
Incyte Corporation
NuCana plc
Medicenna Therapeutics, Inc.
Thomas Jefferson University
Turnstone Biologics, Corp.
Merck Sharp & Dohme LLC
Sotio Biotech Inc.
Nimbus Therapeutics
Eli Lilly and Company
Simcha IL-18, Inc.
Inhibrx Biosciences, Inc
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
ADC Therapeutics S.A.
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
University Hospital, Ghent
University of Florida
Corvus Pharmaceuticals, Inc.
Rutgers, The State University of New Jersey
4D pharma plc
Fate Therapeutics
Xencor, Inc.
Evelo Biosciences, Inc.
Genocea Biosciences, Inc.